Autoimmune haemolysis in patients with B-CLL treated with chlorodeoxyadenosine (CDA)
R C Chasty1, H Myint, D G Oscier
1Department of Haematology, Derriford Hospital, Plymouth, UK.
Leukemia & Lymphoma
|July 31, 1998
Summary
Cladribine (CDA) therapy for B-chronic lymphocytic leukemia (B-CLL) can trigger severe autoimmune hemolytic anemia. This serious side effect is linked to CDA-induced T-lymphocyte depletion, particularly in patients with pre-existing autoimmune tendencies.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- B-chronic lymphocytic leukemia (B-CLL) is a common lymphoid malignancy.
- Cladribine (CDA) is an effective purine analog used in B-CLL treatment.
- Autoimmune complications can occur in B-CLL patients.
Observation:
- Treatment of 19 B-CLL patients with CDA (Leustat) was evaluated.
- Four patients (21%) developed severe autoimmune hemolytic anemia (AIHA).
- Two of these patients experienced severe reticulocytopenia due to red cell aplasia/hypoplasia.
Findings:
- AIHA onset occurred within 4 cycles of CDA therapy.
- Hemolysis onset was temporally related to the T-lymphocyte nadir induced by CDA.
- A positive direct antiglobulin test (DAT) prior to therapy in 3/4 patients suggested CDA-induced T-lymphocytopenia may exacerbate autoimmune tendencies.
Implications:
- CDA therapy carries a risk of severe autoimmune hemolytic anemia in B-CLL patients.
- Monitoring for AIHA is crucial during CDA treatment, especially in patients with positive DAT.
- Understanding the mechanism of CDA-induced T-lymphocytopenia is important for managing autoimmune complications.
